Skyrizi vs Dupixent
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
| US Skyrizi | US Dupixent | |
|---|---|---|
| Generic name | risankizumab | dupilumab |
| Drug class | IL-23 Inhibitor (Biologic) | IL-4/IL-13 Inhibitor (Biologic) |
| Treats | Plaque psoriasis, psoriatic arthritis, Crohn's disease | Eczema, asthma, nasal polyps |
| Category | Autoimmune | Autoimmune |
| Manufacturer | AbbVie | Sanofi/Regeneron |
| Year approved | 2019 | 2017 |
| FDA warning | Moderate warnings | No boxed warning |
| Est. TV ad spend | $480M | $390M |
| Common side effects | Respiratory infections, Headache, Fatigue, Injection site reactions | Injection site reactions, Eye inflammation (conjunctivitis), Cold sores, Eosinophilia |
Frequently asked questions
Is Skyrizi or Dupixent better?
Neither is universally "better." Skyrizi (risankizumab) and Dupixent (dupilumab) are both used for autoimmune, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Skyrizi and Dupixent?
Skyrizi is a IL-23 Inhibitor (Biologic) made by AbbVie, while Dupixent is a IL-4/IL-13 Inhibitor (Biologic) made by Sanofi/Regeneron. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Skyrizi has the larger estimated TV advertising budget of the two.